Market News & Trends
Nutcracker Therapeutics Announces Publication in ACS Nano Demonstrating the Therapeutic Viability of Nutshell Delivery Vehicles
Nutcracker Therapeutics, Inc. recently announced the publication of its latest peer-reviewed paper, which explores the fundamental aspects of its Nutshell platform of peptoid-based mRNA delivery vehicles.…
Agios to Receive $1.1 Billion in Milestone Payments
Agios Pharmaceuticals, Inc. recently announced it will receive a total of $1.1 billion in milestone payments following US FDA approval of vorasidenib for adult and…
Silo Pharma Announces Partnership With Global CRO for CNS Homing Peptide
Silo Pharma, Inc. recently announced it has entered into an agreement with WuXi AppTec (Hong Kong) Limited for a preclinical small animal study of SPU-16,…
Levicept Announces Positive Results of Phase 2 Trial of Novel Neurotrophin-3 Inhibitor for the Treatment of Patients With Moderate to Severe Osteoarthritis
Levicept Ltd recently announced positive results from its Phase 2 trial of LEVI-04 a novel and first in class neurotrophin-3 (NT-3) inhibitor, showing that LEVI-04…
George Medicines Files NDA for Novel Low Dose Triple Combination for Treatment of Hypertension Following Successful Phase 3 Development Program
George Medicines recently announced its submission to the US FDA of a New Drug Application (NDA) for GMRx2, George Medicines’ lead pipeline candidate for the…
Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
Annovis Bio Inc. recently announced new preclinical data demonstrating the synergistic effect of its lead compound, buntanetap, when combined with the glucagon-like peptide 1 (GLP-1)…
Compass Therapeutics Completes Patient Enrollment in Randomized Study of CTX-009 in Combination With Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer
Compass Therapeutics, Inc. recently announced it completed enrollment of the planned 150 patients in COMPANION-002, its randomized Phase 2/3 clinical trial of CTX-009 in patients…
Lonza Upgrades Clinical Manufacturing Services at Bend (US) Site to Include Bottling & Labeling Capabilities
Lonza, a global partner to the pharmaceutical, biotech, and nutraceutical markets, recently announced the addition of clinical bottling and labeling capabilities at its Small Molecules…
New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug
Clearmind Medicine Inc. recently announced a new article published by Baraghithy et al, revealed promising results from a recent study on 5-methoxy-2-aminoindane (MEAI) for combating…
NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02 for Patients Afflicted With Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate
NeOnc Technologies Holdings, Inc. has begun patient enrollment for the Phase 2 clinical trial of NEO100-02, the company’s first of two drug candidates proceeding through…
Salubris Biotherapeutics Announces Approval to Initiate Phase 1 Clinical Trial of a 5T4-Targeted ADC in Solid Tumors
Salubris Biotherapeutics, Inc. recently announced it has received approval from the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of JK06 in…
FDA Review of PsiGAD2 IND Complete; Clinical Trial for Psilocybin-Assisted Psychotherapy in Patients With Generalized Anxiety Disorder to Proceed
Incannex Healthcare Inc. recently announced it has received approval from the US FDA to conduct its Investigational New Drug (IND) opening Phase 2 clinical trial.…
MBX Biosciences Raises $63.5 Million to Advance Precision Endocrine Peptide Platform
MBX Biosciences, Inc. recently announced a $63.5-million Series C financing led by Deep Track Capital, with participation from new investors Driehaus Capital Management and funds…
Cresset Collaborates With Enamine to Enable the Design of Exciting New Targeted Protein Degraders
Cresset recently announced an extension of the global collaboration with Enamine, the world’s leading chemical and biological contract research organization and producer of novel building…
Shapiro Administration Invests Nearly $3 Million to Bring Adare Pharma Solutions’ Headquarters to Pennsylvania
Governor Josh Shapiro recently announced the Commonwealth is investing nearly $3 million in Adare Pharma Solutions to support the life sciences company’s growth and headquarters relocation…
FDA Accepted BLA for the First & Only Ticagrelor Reversal Agent for Filing & Priority Review
SFJ Pharmaceuticals, (SFJ), Sponsor of the bentracimab Biologics License Application (BLA), and SERB Pharmaceuticals (SERB), who acquired exclusive US rights to bentracimab from SFJ and…
SCHOTT Pharma Introduces Nest Design With More Cavities for Prefillable Polymer Syringes
SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, developed a new nest design for prefillable polymer syringes, which holds a total…
Otsuka Pharmaceutical to Acquire Jnana Therapeutics
Otsuka Pharmaceutical Co., Ltd. and Jnana Therapeutics Inc. recently announced they have entered into a definitive merger agreement pursuant to which Otsuka will acquire Jnana,…
DiamiR Biosciences Secures Patent Covering the Use of microRNA Biomarkers From Bodily Fluids for Differential Diagnosis of ALS
DiamiR recently announced its European Patent Application No. 17 771018.3 titled Methods of using miRNAs from bodily fluids for detection and differentiation of neurodegenerative diseases was…
Bayer Submits NDA for Elinzanetant for the Treatment of Moderate to Severe Vasomotor Symptoms Associated With Menopause
Bayer recently announced that a New Drug Application (NDA) for the investigational compound elinzanetant has been submitted to the US FDA for the treatment of…
